Saturday, 31 October 2026European Markets

DNO And PANORO ENERGY Have A High Dividend Yield And Return On Equity In The Oil & Gas E&P Industry.

Loading stream...

(VIANEWS) - DNO (DNO.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Oil & Gas E&P industry.

Financial Asset Price Forward Dividend Yield Return on Equity
DNO (DNO.OL) kr11.28 9.94% 19.33%
PANORO ENERGY (PEN.OL) kr32.90 4.65% 13.44%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. DNO (DNO.OL)

9.94% Forward Dividend Yield and 19.33% Return On Equity

DNO ASA engages in the exploration, development, and production of oil and gas assets in the Middle East, the North Sea, and West Africa. The company holds 75% operating interests in the Tawke and Peshkabir fields, and 64% operating interests in the e Baeshiqa license located in the Kurdistan region of Iraq; has production licenses across 10 fields Norway and two fields in the United Kingdom; and operating interests in the producing Block CI-27, as well as operates the exploration Block CI-12 in West Africa. DNO ASA was founded in 1971 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, DNO has a trailing twelve months EPS of kr-0.54.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.33%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 83.8%, now sitting on 1B for the twelve trailing months.

Sales Growth

DNO's sales growth for the next quarter is negative 27.5%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

DNO's EBITDA is 6.14.

Volume

Today's last reported volume for DNO is 887927 which is 61.3% below its average volume of 2294960.

More news about DNO.

2. PANORO ENERGY (PEN.OL)

4.65% Forward Dividend Yield and 13.44% Return On Equity

Panoro Energy ASA, an independent exploration and production company, engages in the exploration, development, and production of oil and gas properties in Africa. It holds assets in the Equatorial Guinea, Gabon, Tunisia, and South Africa. The company was incorporated in 2009 and is based in London, the United Kingdom.

Earnings Per Share

As for profitability, PANORO ENERGY has a trailing twelve months EPS of kr2.68.

PE Ratio

PANORO ENERGY has a trailing twelve months price to earnings ratio of 12.28. Meaning, the purchaser of the share is investing kr12.28 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.44%.

Yearly Top and Bottom Value

PANORO ENERGY's stock is valued at kr32.90 at 17:40 EST, way under its 52-week high of kr37.15 and way higher than its 52-week low of kr23.70.

Moving Average

PANORO ENERGY's value is higher than its 50-day moving average of kr30.29 and way above its 200-day moving average of kr28.36.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 282.7% and 483.3%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 13.6%, now sitting on 226.25M for the twelve trailing months.

More news about PANORO ENERGY.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com